Detalhe da pesquisa
1.
Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
Diabetes Obes Metab
; 21(5): 1128-1135, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30609212
2.
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.
Diabetes Res Clin Pract
; 138: 253-261, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079379
3.
Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.
Clin Ther
; 39(10): 2024-2037, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28923291
4.
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Curr Med Res Opin
; 33(10): 1861-1868, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28548024